

Clinical Pharmacy

A Newsletter of Drug and Prescribing Information

Prepared by :
Department of Clinical Pharmacy
JSS College of Pharmacy at
JSS Hospital, Mahatma Gandhi Road
Mysuru – 570004

Editors : Dr. M. Ramesh, Ms. Karin Nyfort-Hansen, Ms. Juny Sebastian and Mr. Krishna Undela

Volume 23, Number 1

Jan - Apr 2019

ADVERSE DRUG REACTION REPORTS : SEPT-DEC 2018

A total of 656 Adverse Drug Reactions (ADRs) were reported or detected by the Department of Clinical Pharmacy during September to December 2018. The following are some of the suspected ADRs that were either reported to or detected by the Department of Clinical Pharmacy. In most of the cases there was a change in drug therapy e.g. cessation of suspected drug or reduction in dose, and/or either specific or symptomatic treatment for the suspected ADR.

DRUG(S)	REACTION
Amlodipine + Telmisartan + Hydrochlorothiazide	Small vessel vasculitis
Ceftriaxone	Boil over intrascapular area
Cisplatin	Pulmonary fibrosis
Escitalopram	Erectile dysfunction
Gemcitabine	Systemic capillary leak syndrome
Lamivudine + Efavirenz	Alopecia
Lithium	Plantar ketoderma
Metformin + Glimepiride	Pemphigus vulgaris
Nitrofurantoin (in pregnant woman)	Neonatal jaundice
Norfloxacin + Tinidazole	Fixed drug eruption
Phenytoin + Levetiracetam	DRESS syndrome
Sorafenib	Hand and foot syndrome
Spiroinolactone	Gynecomastia
Tetanus Toxoid injection	Carpopedal spasm
Vancomycin	Red man syndrome

Gemcitabine induced Systemic Capillary Leak Syndrome (SCLS)

Systemic Capillary Leak Syndrome is a rare and potentially fatal disorder characterised by recurrent episodes of generalised oedema, haemoconcentration and severe hypotension. It is hypothesised that SCLS occurs along with gemcitabine pulmonary toxicity (GPT). GPT is thought to be secondary to endothelial dysfunction subsequently causing capillary leakage. Increasing peripheral oedema along with decreasing serum albumin in patients receiving gemcitabine should prompt the clinician to SCLS. Patients with gemcitabine induced SCLS and/or GPT typically respond to systemic steroids. Cessation of gemcitabine is mandatory.

Nitrofurantoin induced Neonatal Jaundice

Nitrofurantoin induced neonatal jaundice is a rare reaction that occurs in neonates exposed to nitrofurantoin 30 days before delivery. It is found that there is a significant higher rate of neonates developing jaundice when exposed to nitrofurantoin than the unexposed neonates. The exact mechanism is unknown but the hypothesis is that the ability of nitrofurantoin to cause hemolytic anemia may favor the cause of neonatal jaundice.

Sorafenib induced Hand and Foot Syndrome

Sorafenib induced hand and foot syndrome is a dose dependent syndrome which is characterized by symmetric painful erythematous plaques in the palmoplantar areas, which include the dorsum of hands & feet and periungual areas. Various possible mechanisms have been evaluated for sorafenib induced hand and foot syndrome, among which the anti-vascular endothelial growth factor property has been hypothesized to be the probable pathogenesis. The treatment includes reduction of dose or cessation of the drug, moisturizers, topical or systemic steroids, tazarotene 0.1% cream, nicotine patch, vitamin E, pyridoxine and cyclooxygenase inhibitor 2 for severe reactions.

We encourage you to report all suspected adverse drug reactions to Department of Clinical Pharmacy. Adverse drug reaction reporting forms are available at all nursing stations. Alternatively you may call Department of Clinical Pharmacy on 2335555 Extn. 5577 or SMS to 9035664802 (Format: ADR / IP or OP Number / Name of the patient / Ward)

DRUGS APPROVED BY US FDA

The following are the drugs that are approved by the US Food and Drug Administration (FDA) during the period September-December 2018

DRUG	BRAND	INDICATION
Dermatology		
Omadacycline	Nuzyra	For the treatment of acute bacterial skin and skin structure infections
Sarecycline	Seysara	For the treatment of moderate to severe acne vulgaris in patients 9 years of age and older
Gastroenterology		
Rifaximin	Aemcolo	For the treatment of traveler's diarrhea
Prucalopride	Motegrity	For the treatment of chronic idiopathic constipation
Immunology		
Emapalumab-lzsg	Gamifant	For the treatment of primary hemophagocytic lymphohistiocytosis
Elapegademase-lvlr	Revcovi	For the treatment of adenosine deaminase severe combined immune deficiency
Ravulizumab-cwvz	Ultomiris	For the treatment of paroxysmal nocturnal hemoglobinuria
Infections and Infectious Diseases		
Omadacycline	Nuzyra	For the treatment of community-acquired bacterial pneumonia
Eravacycline	Xerava	For the treatment of complicated intra-abdominal infections
Baloxavirmarboxil	Xofluza	For the treatment of acute uncomplicated influenza
Neurology		
Inotersen	Tegsedi	For the treatment of the polyneuropathy of hereditary transthyretin mediated amyloidosis in adults
Oncology		
Pembrolizumab	Keytruda	For the treatment of Merkel cell carcinoma
Cemiplimab-rwlc	Libtayo	For the treatment of cutaneous squamous cell carcinoma
Calaspargase pegol-mknl	Asparlas	For the treatment of acute lymphoblastic leukemia in pediatrics and young adults
Duvelisib	Copiktra	For the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma or follicular lymphoma
Glasdegib	Daurismo	For the treatment of newly-diagnosed acute myeloid leukemia in adults 75 years of age or older
Tagraxofusp-erzs	Elzonris	For the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and pediatrics
Moxetumomabpasudotox-tdf	Lumoxiti	For the treatment of relapsed or refractory hairy cell leukemia
Gilteritinib	Xospata	For the treatment of acute myeloid leukemia with a FLT3 mutation
Talazoparib	Talzenna	For the treatment of deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer
Larotrectinib	Vitrakvi	For the treatment of solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion
Dacomitinib	Vizimpro	For the treatment of metastatic non-small cell lung cancer
Lorlatinib	Lorbrena	For the treatment of ALK-positive metastatic non-small cell lung cancer
Pulmonary/Respiratory Diseases		
Omadacycline	Nuzyra	For the treatment of community-acquired bacterial pneumonia
Dupilumab	Dupilixent	For the treatment of moderate-to-severe asthma
Revefenacin	Yupelri	For the maintenance treatment of chronic obstructive pulmonary disease

Reference : <https://www.centerwatch.com/drug-information/fda-approved-drugs/>

DRUGS APPROVED BY CDSCO, INDIA

The following are the drugs that are approved by the Central Drugs Standard Control Organization (CDSCO) during the period September- December 2018

DRUG	STRENGTH	INDICATION
Evogliptin Tartrate	5 mg tablets	For treatment of type-2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, when used as a monotherapy or in combination with Metformin
Lorcaserin Hydrochloride	10 mg tablets	An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m ² or greater (obese) or 27 kg/m ² or greater (overweight) in the presence of at one weight related comorbid condition (e.g. Hypertension, dyslipidaemia, type 2 diabetes)
Fimasartan potassium trihydrate	30mg/60mg/120mg film coated tablets	For the treatment of mild hypertension
Sacubitril/ Valsartan (as sodium salt complex)	50 (24+26) mg/ 100 (49+51) mg/ 200 (97+103) mg film coated tablets	To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction

Reference : https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MzIwNw==

Good News to MDR-TB Patients: Delamanid to be Available Across the Country

India currently has the world's highest burden of Tuberculosis (TB), with 27% of all global cases and over 30% of all deaths worldwide. World Health Organization (WHO) report estimates that India has 1,47,000 multi-drug resistant TB (MDR-TB) patients.

The Ministry of Health and Family Welfare (MoHFW), Govt. of India is planning to make life-saving anti-TB drug Delamanid available across the country. It is the only drug that the World Health Organisation has approved for use in MDR-TB patients in the age group of 6-17 years. The patients in this age group cannot use Bedaquiline, another new drug to treat MDR-TB.



Though the Health Ministry has received 400 courses of Delamanid from United States Agency for International Development (USAID), the distribution has so far been restricted to just seven states (Punjab, Rajasthan, Karnataka, Odisha, Kerala, Chandigarh and Lakshadweep).

On February 5, a letter from Central TB Division in the MoHFW, to all States requested them to send their requirement of Delamanid based on the estimated patient load in the 6-17 age group. In the letter, also mentioned that Delamanid will be offered to patients who have developed resistance to fluoroquinolones and second-line injectables.

At present, most of the MDR-TB cases are treated with kanamycin and capreomycin injections, along with fluoroquinolones. But this therapy has serious side-effects including hearing loss and kidney ailments. Moreover, patients have to visit a facility every day for six months to take injections. All these factors often lead to high dropout from treatment.

References : <http://www.tbonline.info/posts/2019/2/10/india-delamanid-be-available-across-country/>

Tafenoquine: First Single-Dose Medicine to Prevent the Relapse of *P. Vivax* Malaria

In 2016, an estimated 216 million cases of malaria occurred worldwide. *Plasmodium falciparum* is the most prevalent malaria parasite in sub-Saharan Africa, accounting for 99% of estimated malaria cases in 2016. Outside of Africa, *P. vivax* is the predominant parasite in the WHO Region of the Americas, representing 64% of malaria cases, and is above 30% in the WHO South-East Asia and 40% in the Eastern Mediterranean regions.

P. vivax (as well as *P. ovale*) has dormant liver stages (“hypnozoites”) that can activate and invade the blood

(“relapse”) several months or years after the infecting mosquito bite. For over 60 years, the radical cure (prevention of relapse) of *P. vivax* has relied on administering chloroquine to kill the blood stages and then giving primaquine, which is the only licensed anti-malarial with the proven ability to eliminate the hypnozoites. However, primaquine requires a 14-day regimen to be effective, and since the patients are usually feeling better after a few days, they rarely continue to complete the full course.

GlaxoSmithKline (GSK) and Medicines for Malaria Venture

(MMV) jointly developed “Tafenoquine”, 8-aminoquinoline derivative and a synthetic analog of primaquine which acts against the *P. vivax* life-cycle, including hypnozoites. Krintafel (Tafenoquine)

Krintafel was approved in July 2018 by the U.S. Food and Drug Administration for the radical cure of *P. Vivax* malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute *P. vivax* infection (e.g., chloroquine). It was also approved by the Australian Therapeutic Goods Administration in September 2018 for the same indication. It has been submitted by GSK to the Bra-zilian Health Regulatory Agency (ANVI-SA) under a priority review in September 2018.

The dose of Krintafel is 300mg single-dose (as two 150 mg Krintafel tablets taken together) and it is the first ever single-dose approved for radical cure of *P. Vivax* malaria. The primary evidence for the clinical efficacy and safety was obtained from three randomised, double-blind studies: DETECTIVE Part 1 and Part 2 (TAF112582) and GATHER (TAF116564) included more than 800 subjects.

Tafenoquine has a long elimination half-life (average terminal half-life of 15 days). It has slow clearance of blood stage parasites, so it is taken in combination with a faster-acting blood schizonticide, chloroquine.

Reference: 1. Krintafel: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf

DEPARTMENT ACTIVITIES

Pharmacy Practice Module Advanced Learning Series on New Infectious Diseases

Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research (JSS AHER), Mysuru in association with Indian Association of Colleges of Pharmacy (IACP), Chennai organized 'Pharmacy Practice Module - Advanced Learning Series on New Infectious Diseases' from 24th-26th November 2018 at JSS College of Pharmacy, Mysuru. The theme of this three days course was '*the development of strategies and key activities to respond effectively and efficiently to the new infectious diseases*'.

The program was inaugurated on 24th November 2018 by Dr.

B. Suresh, Vice Chancellor, JSS AHER, and President, Pharmacy Council of India (PCI), New Delhi. Prof. K. Chinnaswamy, President, IACP, Chennai and other officials of JSS AHER and IACP were present during the inauguration.

Prof. Krishna Kumar, Howard University, USA, Dr. Miranda Nelson, St. Louis Children's Hospital, USA and Prof. Elias B. Chahine, Palm Beach Atlantic University, USA were the resource persons for Pharmacy Practice Module.

A total of 510 Pharm.D and Postgraduate Pharmacy Practice students and faculty from 34 different Pharmacy institutions across India participated in this program.



Inauguration of Pharmacy Practice Module



Participants with Speakers and Organizing Committee

Workshop on Basics of Clinical Trials Special Reference to Vaccine Trials

Clinical Development Services Agency - Centre for Clinical and Research Excellence (CDSA-CCRE), JSS Academy of Higher Education & Research in collaboration with Department of Clinical Pharmacy, JSS Hospital, Mysuru and Department of Paediatrics, JSS Medical College, Mysuru organized a Workshop on '**Basics of Clinical Trials-**

Special Reference to Vaccine Trials' on 6th December 2018 at JSS Hospital, Mysuru. The aim of this workshop was to train the healthcare professionals on clinical trial regulations pertaining to vaccines. A total of 59 participants from Karnataka and Tamil Nadu attended the workshop.



Participants with Speakers and Organizing Committee

Series of Workshops on Pharmacovigilance

The Department of Clinical Pharmacy located at JSS Hospital, Mysuru, as a part of 'Regional Training Centre for South Zone' under Pharmacovigilance Programme of India (PvPI), Ministry of Health & Family Welfare (MoHFW), Govt. of India extended the technical support and expertise to **NET College of Pharmacy, Raichur** in conducting 'National Workshop on Current Perspectives on Pharmacovigilance and Hemovigilance' on 28th & 29th September 2018.

The theme of the workshop was '*Medication use without harm for enhanced patient care*'. The workshop aimed to provide training on Pharmacovigilance and Hemovigilance advance the knowledge among Pharmacy students. **Dr. M. Ramesh**, Professor & Head, **Mrs. Juny Sebastian** and **Mr. Krishna Undela**, Lecturers, Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru were the resource persons for this workshop.



Dr. M. Ramesh, Mrs. Juny Sebastian and Mr. Krishna Undela delivering the lectures

A total of 260 healthcare professionals, postgraduate medical students, Pharm.D interns from different institutions located across the country attended this workshop.

The Department of Clinical Pharmacy extended the technical support and expertise to **Pondicherry Institute of Medical Sciences (PIMS), Puducherry** in conducting National Workshop on Advanced Pharmacovigilance' on 9th & 10th November 2018. The workshop aimed to provide training on advanced Pharmacovigilance methods amongst healthcare professionals. A total of 43 healthcare professionals, postgraduate medical students, Pharm.D interns from different institutions located across the country attended this workshop. Participants were expressed their satisfaction with the topics covered and hands-on sessions conducted during the workshop.



Participants with Speakers and Organizing Committee

The Regional Training Centre for South Zone, JSS Medical College & Hospital, Mysuru in association with Dept. of Pharmacy Practice, **JSS College of Pharmacy, JSS AHER, Mysuru** and National Coordinating Centre for PvPI, Indian Pharmacopoeia Commission, Ghaziabad organized two days "Advanced Level Workshop on Pharmacovigilance" on 21st & 22nd December 2018 at JSS College of Pharmacy, Mysuru. About 25 Pharmacovigilance coordinators & patient safety Pharmacovigilance associates of Adverse Drug Reaction Monitoring Centres (AMC) located in Karnataka, Kerala, Tamil Nadu and Pudicherry attended this workshop.

The aim of this workshop was to provide training in order to advance the knowledge and develop skills amongst pharmacovigilance coordinators and patient safety




Inauguration of Advanced Level Workshop on Pharmacovigilance pharmacovigilance associates working for AMC under PvPI, MoHFW, Govt. of India. Participants were gratified with the new topics covered during the workshop.

Faculty Attended International Conferences

Mr. Krishna Undela, Mrs. Juny Sebastian and **Dr. Umesh M.** Lecturers, Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru attended the International Society for Pharmacoepidemiology's (ISPE's) **11th Asian Conference on Pharmacoepidemiology (ACPE)** held at Hotel Wyndham Grand, **Xi'an, China** from 27th 29th October 2018.

Faculty attended Educational Session on 27th October 2018 and main conference on 28th & 29st October 2018. During Educational Session, Mr. Krishna Undela delivered a talk on 'Principles of analytic Pharmacoepidemiological study designs'. During the main conference faculty presented posters of their research work.




Mr. Krishna Undela, Mrs. Juny Sebastian and Dr. Umesh M. during Poster Presentation

Faculty received scholarship of 9000 Renminbi & complimentary registration from ISPE to attend the conference. During this conference, faculty had an opportunity to meet and network with internationally

recognized experts in the area of Pharmacoepidemiology and drug safety. Also they had an opportunity to exchange research ideas and current practices with fellow delegates for the mutual benefit.

Mr. Sri Harsha Chalasani, Lecturer, Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru attended the **International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific Conference** from 8th to 11th September 2018 at Keio Plaza, **Tokyo, Japan**. He presented a poster titled “*Stewardship of medication errors in a developing country's scenario: a clinical pharmacist's role*”. He was awarded with USD 1800 and complementary registration from ISPOR for attending the conference.



Mr. Sri Harsha during Poster Presentation

Outreach Programs Organized

Blood Donation Camp

Department of Pharmacy Practice in association with National Service Scheme (NSS) Unit of JSS College of Pharmacy, Mysuru organised a blood donation camp on **8th December 2018** at JSS College of Pharmacy, Sri Shivarathreshwara Nagar, Mysuru on the occasion of National Pharmacy Week Celebration. During the camp, around 100 registered volunteers were screened, and a total of 41 units of blood were collected from the student volunteers. **Dr. M. P. Gowrav**, NSS Program Officer, and **Dr. M. Umesh**, Lecturer, Department of Pharmacy Practice coordinated the blood donation camp.



Inauguration of Blood Donation Camp

Forensic Fair 2018

Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru had put up a stall on **Poison Information Centre (PIC)** during 'Forensic Fair 2018' organized by the Department of Forensic Medicine and Toxicology, JSS Medical College, Mysuru from **19th- 21st December 2018** at the campus of JSS Hospital, Mysuru. Through the PIC stall, Department created an awareness amongst school children and general public on existence of PIC at Department of Clinical Pharmacy, JSS Hospital, Mysuru and the different services provided by PIC in the prevention and management of different types of poisoning cases and also about various first aid measures.



Staff and Students of Department during Forensic Fair 2018

Health Screening Camps

Department of Pharmacy Practice in association with National Service Scheme (NSS), JSS College of Pharmacy, Mysuru organized a Health Screening Camp on the occasion of NSS Day & Golden Jubilee Celebrations of NSS for the benefit of pilgrimages visiting to Chamundi hills on **30th September 2018** between 6 am and 9 am. During the camp, interested public were screened for blood pressure and blood glucose levels. A total of 203 people were monitored for their blood pressure and blood glucose levels.

Department of Pharmacy Practice in collaboration with Indian Pharmaceutical Association (IPA), Mysore Branch organized a Health Screening Camp for the benefit of public of Mysuru city on **5th December 2018** at three different locations Viz., Bal Bhavan, Chamundi Hills Footsteps and



Health Screening Camp @ Lalith Mahal Gate

Lalith Mahal Gate between 6 am and 10 am. In all three venues, a total of 277 people were monitored for their blood pressure and blood glucose levels.

Continuing Professional Development Program

The Department of Pharmacy Practice conducted a Continuing Professional Development (CPD) Program on 'Rational Use of Antibiotics' for Practicing Pharmacists of Mysuru city on 29th September 2018 at JSS College of Pharmacy, Mysuru. The objective of this program was to advance knowledge and develop skills of the practicing pharmacist pertaining to rational use of antibiotics to curb antibiotic resistance. **Mr. M.S. Srikanth**, Lecturer, Department of Pharmacy Practice led the session on 'Rational Use of Antibiotics'. A total of 20 practicing hospital & community pharmacists from various parts of Mysuru city attended this program.



Mr. Srikanth M.S. and Participants of the CPD Program

Series of Guest Lectures

Department of Pharmacy Practice in association with Pharmacy Education Unit (PEU) of JSS College of Pharmacy, Mysuru organised series of Guest Lectures by experts from Pharmaceutical Industry for the benefit of students and staff of the Department. **Mr. Amarnath N**, AVP Sales & Marketing, Vans Scientific Information Pvt. Ltd., Bangalore conducted 'User Orientation Session on Micromedex on 24th September 2018 at JSS Hospital, Mysuru. Micromedex is an online software for evidence-based clinical decision support and referential content, real-time clinical surveillance, and patient education.



Mr. Amarnath N Delivering the Lecture

Mr. Shambho Ghosh, Senior Executive Clinical Affairs and Pharmacovigilance, Biological E Ltd., Hyderabad delivered a guest lecture on 'New Regulation for Clinical Research in India' on 12th October 2018.



Mr. Shambho Ghosh Delivering the Lecture

Mr. Uma Manohar Gopal, Associate Team Lead, Bioclinica, Mysuru, **Dr. Pramod Kumar A** and **Ms. Mallika**, Senior Drug Safety Associates, Bioclinica, Mysuru

delivered series of guest lectures on three topics viz. 'Introduction to Pharmacovigilance', 'National & International Scenario of Pharmacovigilance' and 'Causality Assessment of Adverse Drug Reactions' on 10th November 2018

Ms. Mallika, Senior Drug Safety Associate, Bioclinica, Mysuru delivered a guest lecture on 'The Drug Development Process' on 17th November 2018.



Ms. Mallika Delivering the Lecture

International Students' Clinical Rotation at Department of Clinical Pharmacy

Three students, Ms. Allison Paige Davis, Ms. Alyse Battles and Ms. Olivia Brandner from **Sothern Illinois University, Edwardsville, USA** received five weeks experiential training at Department of Clinical Pharmacy, JSS Hospital, Mysuru from 12th October 11th November 2018 under student study exchange program. Students were posted to Medicine and Pediatrics department for a period of one week each to learn about most common diseases with an emphasis on infectious diseases and their management.



SIUE Students Interacting with Patient

Ms. Leah Osae and Mr. Aakash Patel from **University of North Carolina, Chapel Hill, USA** received five weeks experiential training at Department of Clinical Pharmacy, JSS Hospital, Mysuru from 1-30th October 2018 under student study exchange program. The aim of this experiential training

was to expose the student to an international rotation to gain knowledge and develop practice skills focused on public health and infectious diseases that are common in developing countries.

Five Pharmacy students and a Professor of **LaTrobe University, Australia** visited Department of Clinical Pharmacy at JSS Hospital, Mysuru on 28th September 2018. The students were briefed about drug therapy review with special emphasis on identification of drug related problems and Pharmacists' intervention. Also, they were explained about Adverse Drug Reaction (ADR) reporting system, reporting of medication incidents, Adverse Events Following Immunizations (AEFIs), and patient medication counseling process with a special emphasis on ambulatory patient care & JSS MINDS (medication information for neuropsychiatric disorders & sensitization) initiatives.



Briefing on Department Activities to LaTrobe University Students

Recognitions

Dr. M. Ramesh, Professor & Head, Department of Pharmacy Practice, received the Certificate of appreciation in recognition of the outstanding contribution and remarkable commitment towards the success of JSS AHER in its pursuit for quality and excellence that was presented on 11th October 2018 during 10 years celebration of JSS AHER, Mysuru.

Dr. Umesh M., Lecturer, Department of Pharmacy Practice, received the certificate of appreciation in recognition of voluntary blood donation on the day of National Voluntary Blood Donation 2018.



Dr. Umesh M. (First) Receiving the Award

Dr. M. Ramesh, Professor & Head, Department of Pharmacy Practice, received 'AUSHADA RATNA' award from Indian Pharmaceutical Association, Mysuru Branch for his meritorious contributions and achievements in the field of Pharmacy Education. The award was presented to him on 8th December 2018 during the 57th National Pharmacy Week celebration held during 5th & 8th December 2018 at JSS College of Pharmacy, Mysuru.



Dr. M. Ramesh Receiving the Award

The Drug & Poison Information Service

Our Department can help you with any questions you might have on the use of medicines or the management of poisoned patients. We can also assist you with any medication related problems you face in your daily practice. The services are made available on all working days and it is provided free of cost.

We request you to avail the drug and poison information services.

We extended our services 24x7 from 8th October 2018 for the benefit of HCPs and Patients.

24x7 Mobile Number: 6363539153, Toll free Number - 1800-425-0207, Landline Number: 2335555, Extn - 5577

E-mail: dic.jssep@jssuni.edu.in; pic.jssep@jssuni.edu.in;

Website: www.picjssepm.jssuni.edu.in

Your suggestions are welcome. Please send your comments/suggestions to the editors at: dic.jssep@jssuni.edu.in

To,

Book - Post

